£6M initial fundraising
Successful phase II results in cat allergy
3rd funding round (£15M)
Positive phase II results in house dust mite & ragweed allergies
£60M investment round
Start of phase III in cat allergy
Results from phase II cat allergy study show four-dose treatment maintains improvement 2 years later
18 March: Circassia raises £200M in successful IPO on the London Stock Exchange
Circassia (CIR:LSE) is a specialty biopharmaceutical company focused on the development of novel immunotherapies. These are designed to treat a range of common allergies and autoimmune conditions by controlling patients’ inappropriate immune responses. Our most advanced treatment, Cat-SPIRE, has achieved highly impressive results in clinical studies, and is currently in the final phase of testing for cat allergy.
Circassia’s pipeline of immunotherapies is based on its unique ToleroMune® technology, and with strong support from its shareholders the Company has made significant progress developing its products following its establishment in 2006. As a private company, we expanded our portfolio of treatments, raised a total of £105 million in investment and successfully completed numerous clinical studies. This progress culminated in a successful initial public offering on the London Stock Exchange on 18 March 2014, and to date the Company has raised over £300 million in investment. We also continue to maintain strong links with allergy experts, and our joint venture with McMaster University (Hamilton, Canada), Adiga Life Sciences Inc, is pursuing promising new science in the field.
Circassia’s ultimate ambition is to build a successful financially self-sustaining specialty biopharma company, focused on improving patients’ lives around the world. In the short term, we plan to complete the development and launch of our first allergy treatment, Cat-SPIRE. To achieve this, we are building our commercial capabilities and advancing our phase III program. With the support of our investors, Circassia is making good progress towards meeting its long-term goal.